<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833075</url>
  </required_header>
  <id_info>
    <org_study_id>ELICIT</org_study_id>
    <nct_id>NCT04833075</nct_id>
  </id_info>
  <brief_title>Real World Pharmacokinetics of Immune Checkpoint Inhibitors</brief_title>
  <acronym>ELICIT</acronym>
  <official_title>Real World Pharmacokinetics of Immune Checkpoint Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Real-world pharmacokinetic data from cancer patients treated with immune&#xD;
      checkpoint inhibitors (ICIs) are sparse. Moreover, pharmacokinetic parameters may be&#xD;
      associated with response to ICI treatment and may act as a predictive or early response&#xD;
      biomarker.&#xD;
&#xD;
      Objective: To describe the real-world pharmacokinetics of ICIs in patients eligible for ICI&#xD;
      treatment or already treated with ICIs.&#xD;
&#xD;
      Study design: A low-interventional cross-sectional pharmacokinetic study. Study population:&#xD;
      Patients treated with ICIs. Intervention: A maximum of 13 blood samples (39 mL) will be&#xD;
      derived from subjects on treatment. After discontinuation of ICI treatment, a maximum of 7&#xD;
      blood samples (21 mL) will be derived.&#xD;
&#xD;
      Main study parameters: Real- world pharmacokinetic parameters of ICIs: clearance, volume of&#xD;
      distribution, serum exposure (serum concentration - time curve).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A low-interventional cross-sectional pharmacokinetic study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Real-world pharmacokinetic parameters --&gt; clearance</measure>
    <time_frame>t=0 until t=12 months or end-of-treatment, whichever comes first (on-treatment) and t=0 until max. t=26 weeks (after discontinuation)(depends on ICI used)</time_frame>
    <description>baseline clearance, change of clearance during treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Real-world pharmacokinetic parameters --&gt; volume of distribution</measure>
    <time_frame>t=0 until t=12 months or end-of-treatment, whichever comes first (on-treatment) and t=0 until max. t=26 weeks (after discontinuation)(depends on ICI used)</time_frame>
    <description>volume of distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Real-world pharmacokinetic parameters --&gt; exposure</measure>
    <time_frame>t=0 until t=12 months or end-of-treatment, whichever comes first (on-treatment) and t=0 until max. t=26 weeks (after discontinuation)(depends on ICI used)</time_frame>
    <description>serum exposure (serum concentration - time curve)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>additional blood sampling (single arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>A maximum of 13 blood samples (39 mL) will be derived from subjects on treatment. After discontinuation of ICI treatment, a maximum of 7 blood samples (21 mL) will be derived.</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treatment with immune checkpoint inhibitors (atezolizumab (Tecentriq®), avelumab&#xD;
             (Bavencio®), cemiplimab (Libtayo®), durvalumab (Imfinzi®), ipilimumab (Yervoy®),&#xD;
             nivolumab (Opdivo®) and pembrolizumab (Keytruda®))&#xD;
&#xD;
          -  Willingness and ability to provide written informed consent&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
        Exclusion Criteria: n/a (real-world)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leila S Otten, PharmD</last_name>
    <phone>+31 6 29501773</phone>
    <email>Leila-Sophie.Otten@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rob ter Heine, PhD</last_name>
    <phone>+31-24-36 17744</phone>
    <email>r.terheine@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila Otten, PharmD</last_name>
      <email>leila-sophie.otten@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Rob ter Heine, PhD</last_name>
      <email>R.terHeine@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune Checkpoint Inhibitor</keyword>
  <keyword>Pharmacokinetics</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

